• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    United Therapeutics Corporation Reports First Quarter 2025 Financial Results

    4/30/25 6:30:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UTHR alert in real time by email

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024.

    "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout of TETON 2 in idiopathic pulmonary fibrosis and the planned commencement of our UKidney first in human clinical study, respectively. Moreover, we're excited to advance our multiple shots on goal approach to creating an unlimited supply of transplantable organ alternatives with anticipated filings of investigational new drug applications with the FDA for our UHeart and UThymoKidney products."

    Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, added, "This quarter's record revenue performance reflects the diligent efforts and strategic focus of our commercial team as we continue to expand our reach and solidify our position in the pulmonary hypertension marketplace as the prostacyclin products of choice. We look forward to building on this performance for the remainder of the year."

    First Quarter 2025 Financial Results

    Key financial highlights include (dollars in millions, except per share data):

     

    Three Months

    Ended

    March 31,

     

    Dollar

    Change

     

    Percentage

    Change

     

    2025

     

    2024

     

     

     

     

     

     

     

     

     

     

    Total revenues

    $

    794.4

     

    $

    677.7

     

    $

    116.7

     

    17

    %

    Net income

    $

    322.2

     

    $

    306.6

     

    $

    15.6

     

    5

    %

    Net income, per basic share

    $

    7.18

     

    $

    6.52

     

    $

    0.66

     

    10

    %

    Net income, per diluted share

    $

    6.63

     

    $

    6.17

     

    $

    0.46

     

    7

    %

    Revenues

    The table below presents the components of total revenues (dollars in millions):

     

    Three Months

    Ended

    March 31,

     

    Dollar

    Change

     

    Percentage

    Change

     

    2025

     

    2024

     

     

    Net product sales:

     

     

     

     

     

     

     

    Tyvaso DPI®(1)

    $

    302.5

     

    $

    227.5

     

    $

    75.0

     

     

    33

    %

    Nebulized Tyvaso®(1)

     

    163.8

     

     

    145.0

     

     

    18.8

     

     

    13

    %

    Total Tyvaso

     

    466.3

     

     

    372.5

     

     

    93.8

     

     

    25

    %

    Remodulin®(2)

     

    138.2

     

     

    128.0

     

     

    10.2

     

     

    8

    %

    Orenitram®

     

    120.7

     

     

    106.2

     

     

    14.5

     

     

    14

    %

    Unituxin®

     

    58.2

     

     

    58.4

     

     

    (0.2

    )

     

    —

    %

    Adcirca®

     

    6.0

     

     

    6.4

     

     

    (0.4

    )

     

    (6

    )%

    Other

     

    5.0

     

     

    6.2

     

     

    (1.2

    )

     

    (19

    )%

    Total revenues

    $

    794.4

     

    $

    677.7

     

    $

    116.7

     

     

    17

    %

     

    (1)

    Net product sales include both the drug product and the respective inhalation device.

    (2)

    Net product sales include sales of infusion devices, including the Remunity® Pump.

    Total Tyvaso revenues grew by 25 percent to $466.3 million in the first quarter of 2025, compared to $372.5 million in the first quarter of 2024.

    The growth in Tyvaso DPI revenues resulted primarily from an increase in quantities sold of $97.4 million and, to a lesser extent, a price increase, partially offset by higher gross-to-net deductions. The increase in Tyvaso DPI quantities sold was primarily due to continued growth in the number of patients following the product's launch, including growth in utilization by patients with pulmonary hypertension associated with interstitial lung disease and, to a lesser extent, increased commercial utilization following the implementation of the Medicare Part D benefit redesign under the Inflation Reduction Act (IRA).

    The growth in nebulized Tyvaso revenues resulted primarily from an increase in international nebulized Tyvaso revenues, driven by the timing of orders by our international distributors and does not precisely reflect trends in underlying patient demand.

    The growth in Remodulin revenues resulted primarily from an increase in U.S. Remodulin revenues, driven by an increase in quantities sold.

    The growth in Orenitram revenues resulted primarily from an increase in quantities sold and, to a lesser extent, a price increase, partially offset by higher gross-to-net deductions. The increase in quantities sold was driven, at least in part, by increased commercial utilization following the implementation of the Medicare Part D benefit redesign under the IRA.

    The table below presents the breakdown of total revenues between the United States and rest-of-world (ROW) (dollars in millions):

     

    Three Months Ended March 31,

     

    2025

     

    2024

     

    U.S.

    ROW

    Total

     

    U.S.

    ROW

    Total

    Net product sales:

     

     

     

     

     

     

     

    Tyvaso DPI(1)

    $

    302.5

    $

    —

    $

    302.5

     

    $

    227.5

    $

    —

    $

    227.5

    Nebulized Tyvaso(1)

     

    138.6

     

    25.2

     

    163.8

     

     

    133.7

     

    11.3

     

    145.0

    Total Tyvaso

     

    441.1

     

    25.2

     

    466.3

     

     

    361.2

     

    11.3

     

    372.5

    Remodulin(2)

     

    120.2

     

    18.0

     

    138.2

     

     

    108.3

     

    19.7

     

    128.0

    Orenitram

     

    120.7

     

    —

     

    120.7

     

     

    106.2

     

    —

     

    106.2

    Unituxin

     

    56.9

     

    1.3

     

    58.2

     

     

    53.4

     

    5.0

     

    58.4

    Adcirca

     

    6.0

     

    —

     

    6.0

     

     

    6.4

     

    —

     

    6.4

    Other

     

    4.7

     

    0.3

     

    5.0

     

     

    6.0

     

    0.2

     

    6.2

    Total revenues

    $

    749.6

    $

    44.8

    $

    794.4

     

    $

    641.5

    $

    36.2

    $

    677.7

     

    (1)

    Net product sales include both the drug product and the respective inhalation device.

    (2)

    Net product sales include sales of infusion devices, including the Remunity Pump.

    Expenses

    Cost of sales. The table below summarizes cost of sales by major category (dollars in millions):

     

    Three Months

    Ended

    March 31,

     

    Dollar

    Change

     

    Percentage

    Change

     

    2025

     

    2024

     

     

    Category:

     

     

     

     

     

     

     

    Cost of sales

    $

    91.6

     

    $

    71.8

     

    $

    19.8

     

     

    28

    %

    Share-based compensation expense(1)

     

    0.9

     

     

    1.1

     

     

    (0.2

    )

     

    (18

    )%

    Total cost of sales

    $

    92.5

     

    $

    72.9

     

    $

    19.6

     

     

    27

    %

     

    (1)

    See Share-based compensation below.

    Cost of sales, excluding share-based compensation. Cost of sales for the three months ended March 31, 2025 increased as compared to the same period in 2024, primarily due to an increase in royalty expense and product costs, particularly for Tyvaso DPI driven by growth in Tyvaso DPI revenues.

    Research and development. The table below summarizes the nature of research and development expense by major expense category (dollars in millions):

     

    Three Months

    Ended

    March 31,

     

    Dollar

    Change

     

    Percentage

    Change

     

    2025

     

    2024

     

     

    Category:

     

     

     

     

     

     

     

    External research and development(1)

    $

    57.2

     

    $

    52.7

     

    $

    4.5

     

    9

    %

    Internal research and development(2)

     

    48.3

     

     

    44.9

     

     

    3.4

     

    8

    %

    Share-based compensation expense(3)

     

    6.9

     

     

    6.4

     

     

    0.5

     

    8

    %

    Other(4)

     

    36.6

     

     

    0.1

     

     

    36.5

     

    NM(5)

    Total research and development expense

    $

    149.0

     

    $

    104.1

     

    $

    44.9

     

    43

    %

     

    (1)

    External research and development primarily includes fees paid to third parties (such as clinical trial sites, contract research organizations, and contract laboratories) for preclinical and clinical studies and payments to third-party contract manufacturers before FDA approval of the relevant product.

     

    (2)

    Internal research and development primarily includes salary-related expenses for research and development functions, internal costs to manufacture product candidates before FDA approval, and internal facilities-related expenses, including depreciation, related to research and development activities.

     

    (3)

    See Share-based compensation below.

     

    (4)

    Other primarily includes upfront fees and milestone payments to third parties under license agreements related to development-stage products and adjustments to the fair value of our contingent consideration obligations.

     

    (5)

    Calculation is not meaningful.

    Research and development, excluding share-based compensation. Research and development expense for the three months ended March 31, 2025 increased as compared to the same period in 2024, primarily due to: (1) an increase of $30.0 million related to milestone payments for drug delivery device technologies; (2) an increase of $6.6 million related to adjustments to the fair value of our contingent consideration obligations for manufactured organ and organ alternative projects; and (3) increased expenditures related to manufactured organ and organ alternative projects.

    Selling, general, and administrative. The table below summarizes selling, general, and administrative expense by major category (dollars in millions):

     

    Three Months

    Ended

    March 31,

     

    Dollar

    Change

     

    Percentage

    Change

     

    2025

     

    2024

     

     

    Category:

     

     

     

     

     

     

     

    General and administrative

    $

    119.5

     

    $

    103.1

     

    $

    16.4

     

    16

    %

    Sales and marketing

     

    26.6

     

     

    23.2

     

     

    3.4

     

    15

    %

    Share-based compensation expense(1)

     

    24.0

     

     

    18.1

     

     

    5.9

     

    33

    %

    Total selling, general, and administrative expense

    $

    170.1

     

    $

    144.4

     

    $

    25.7

     

    18

    %

     

    (1)

    See Share-based compensation below.

    General and administrative, excluding share-based compensation. General and administrative expense for the three months ended March 31, 2025 increased as compared to the same period in 2024, primarily due to an increase in personnel expense due to growth in headcount.

    Share-based compensation. The table below summarizes share-based compensation expense by major category (dollars in millions):

     

    Three Months

    Ended

    March 31,

     

    Dollar

    Change

     

    Percentage

    Change

     

    2025

     

    2024

     

     

    Category:

     

     

     

     

     

     

     

    Stock options

    $

    8.5

     

     

    $

    5.7

     

    $

    2.8

     

     

    49

    %

    Restricted stock units

     

    23.4

     

     

     

    15.5

     

     

    7.9

     

     

    51

    %

    Share tracking awards plan

     

    (0.8

    )

     

     

    3.9

     

     

    (4.7

    )

     

    (121

    )%

    Employee stock purchase plan

     

    0.7

     

     

     

    0.5

     

     

    0.2

     

     

    40

    %

    Total share-based compensation expense

    $

    31.8

     

     

    $

    25.6

     

    $

    6.2

     

     

    24

    %

     

    Other (expense) income, net. The change in other (expense) income, net for the three months ended March 31, 2025, as compared to the same period in 2024, was primarily due to net unrealized losses on equity securities.

    Income tax expense. Income tax expense for the three months ended March 31, 2025 and 2024 was $101.3 million and $92.0 million, respectively. Our effective income tax rate (ETR) for the three months ended March 31, 2025 and 2024 was 24 percent and 23 percent, respectively. Our ETR for the three months ended March 31, 2025 increased compared to our ETR for the three months ended March 31, 2024, primarily due to decreased excess tax benefits from share-based compensation.

    Webcast

    We will host a webcast to discuss our first quarter 2025 financial results on Wednesday, April 30, 2025, at 9:00 a.m. Eastern Time. The webcast can be accessed live via our website at https://ir.unither.com/events-and-presentations. A replay of the webcast will also be available at the same location on our website.

    United Therapeutics: Enabling Inspiration

    At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun; we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

    You can learn more about what it means to be a PBC here: unither.com/pbc.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements related to our waves of growth, the anticipated readout of the TETON 2 clinical trial in idiopathic pulmonary fibrosis; the planned commencement of our UKidney first in human clinical study; our plan to create an unlimited supply of transplantable organ alternatives; our anticipated filings of investigational new drug applications with the FDA for our UHeart and UThymoKidney products; our plan to continue to expand our reach and solidify our position in the pulmonary hypertension marketplace as the prostacyclin products of choice; our plan to build on our commercial performance for the remainder of the year; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of April 30, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.

    ORENITRAM, REMODULIN, REMUNITY, TYVASO, TYVASO DPI, and UNITUXIN are registered trademarks of United Therapeutics Corporation and/or its subsidiaries.

    UHEART, UKIDNEY, and UTHYMOKIDNEY are trademarks of United Therapeutics Corporation and/or its subsidiaries.

    ADCIRCA is a registered trademark of Eli Lilly and Company.

    UNITED THERAPEUTICS CORPORATION

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (In millions, except per share data)

     

     

    Three Months

    Ended

    March 31,

     

     

    2025

     

     

     

    2024

     

     

    (Unaudited)

    Total revenues

    $

    794.4

     

     

    $

    677.7

     

    Operating expenses:

     

     

     

    Cost of sales

     

    92.5

     

     

     

    72.9

     

    Research and development

     

    149.0

     

     

     

    104.1

     

    Selling, general, and administrative

     

    170.1

     

     

     

    144.4

     

    Total operating expenses

     

    411.6

     

     

     

    321.4

     

    Operating income

     

    382.8

     

     

     

    356.3

     

    Interest income

     

    51.1

     

     

     

    53.8

     

    Interest expense

     

    (6.1

    )

     

     

    (13.3

    )

    Other (expense) income, net

     

    (4.3

    )

     

     

    1.8

     

    Total other income, net

     

    40.7

     

     

     

    42.3

     

    Income before income taxes

     

    423.5

     

     

     

    398.6

     

    Income tax expense

     

    (101.3

    )

     

     

    (92.0

    )

    Net income

    $

    322.2

     

     

    $

    306.6

     

    Net income per common share:

     

     

     

    Basic

    $

    7.18

     

     

    $

    6.52

     

    Diluted

    $

    6.63

     

     

    $

    6.17

     

    Weighted average number of common shares outstanding:

     

     

     

    Basic

     

    44.9

     

     

     

    47.0

     

    Diluted

     

    48.6

     

     

     

    49.7

     

    SELECTED CONSOLIDATED BALANCE SHEET DATA

    (Unaudited, in millions)

     

     

    March 31,

    2025

    Cash, cash equivalents, and marketable investments

    $

    5,032.0

    Total assets

     

    7,743.9

    Total liabilities

     

    936.7

    Total stockholders' equity

     

    6,807.2

    Category: Earnings

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250430348125/en/

    Dewey Steadman at (202) 919-4097 (media/investors)

    Harry Silvers at (301) 578-1401 (investors)

    https://ir.unither.com/contact-ir

    Get the next $UTHR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UTHR

    DatePrice TargetRatingAnalyst
    4/25/2025Overweight → Equal Weight
    Wells Fargo
    4/21/2025$314.00Underperform → Neutral
    BofA Securities
    7/11/2024$310.00 → $321.00Overweight → Equal-Weight
    Morgan Stanley
    2/12/2024$213.00 → $215.00Sell → Neutral
    Goldman
    2/5/2024$330.00Outperform
    Leerink Partners
    12/8/2023$309.00Overweight
    Wells Fargo
    12/6/2022$320.00Buy
    UBS
    12/5/2022$230.00Sell
    Goldman
    More analyst ratings

    $UTHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • United Therapeutics downgraded by Wells Fargo

      Wells Fargo downgraded United Therapeutics from Overweight to Equal Weight

      4/25/25 8:31:30 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded United Therapeutics from Underperform to Neutral and set a new price target of $314.00

      4/21/25 8:09:51 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded United Therapeutics from Overweight to Equal-Weight and set a new price target of $321.00 from $310.00 previously

      7/11/24 7:48:56 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & GENERAL COUNSEL Mahon Paul A exercised 11,000 shares at a strike of $117.76 and sold $3,246,150 worth of shares (11,000 units at $295.10) (SEC Form 4)

      4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

      5/20/25 4:32:10 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thompson Tommy G exercised 2,500 shares at a strike of $175.43 and sold $762,865 worth of shares (2,500 units at $305.15) (SEC Form 4)

      4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

      5/12/25 4:30:23 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & GENERAL COUNSEL Mahon Paul A exercised 11,000 shares at a strike of $117.76 and sold $3,310,201 worth of shares (11,000 units at $300.93) (SEC Form 4)

      4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

      5/2/25 4:31:43 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • United Therapeutics Corporation Reports First Quarter 2025 Financial Results

      United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout

      4/30/25 6:30:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference

      Interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at a mini symposium An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented at a poster session United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Francisco on May 16-21, 2025. At ATS, United Therapeutics is sponsoring several events including the Respiratory Innovation Summit and the

      4/21/25 7:00:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

      United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, April 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and missi

      4/16/25 7:00:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    Financials

    Live finance-specific insights

    See more
    • United Therapeutics Corporation Reports First Quarter 2025 Financial Results

      United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout

      4/30/25 6:30:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

      United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, April 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and missi

      4/16/25 7:00:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

      United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. "I want to congratulate every Unitherian for their relentless dedication, which has allowed us to deliver a third consecutive year of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "On top of that, our three-year cascade of clinical and regulatory events is under way: both TETON studies in idiopathic pulmonary fibrosis are enrolled, facilitating data starting the second half

      2/26/25 6:30:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    Leadership Updates

    Live Leadership Updates

    See more
    • IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors

      WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the

      1/27/21 8:00:00 AM ET
      $CLGN
      $UTHR
      $XERS
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $UTHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by United Therapeutics Corporation

      SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      11/8/24 4:30:29 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by United Therapeutics Corporation

      SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      10/16/24 1:03:48 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)

      SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      6/10/24 12:15:17 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by United Therapeutics Corporation

      SCHEDULE 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      5/12/25 10:44:45 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)

      4/30/25 6:33:10 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by United Therapeutics Corporation

      10-Q - UNITED THERAPEUTICS Corp (0001082554) (Filer)

      4/30/25 6:32:05 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care